ISSN 1662-4009 (online)

ey0016.2-1 | Neonatal Hypoglycaemia | ESPEYB16

2.1. Congenital hyperinsulinism in infants with turner syndrome: possible association with monosomy X and KDM6A haploinsufficiency

CE Gibson , KE Boodhansingh , C Li , L Conlin , P Chen , SA Becker , T Bhatti , V Bamba , NS Adzick , DD De Leon , A Ganguly , CA Stanley

To read the full abstract: Horm Res Paediatr: 2018;89(6):413–422.This study examined the clinical and molecular aspects of girls with Turner syndrome and hyperinsulinaemic hypoglycemia (HH). Records of girls with hyperinsulinism and Turner syndrome were reviewed.The findings expand on previous observations suggesting a link between Turner syndrome and hyperins...

ey0019.11-6 | New findings in adipose tissue biology | ESPEYB19

11.6. Obesity and hyperinsulinemia drive adipocytes to activate a cell cycle program and senesce

Q Li , CE Hagberg , HS Cascales , S Lang , MT Hyvonen , F Salehzadeh , P Chen , I Alexandersson , E Terezaki , MJ Harms , M Kutschke , N Arifen , N Kramer , M Aouadi , C Knibbe , J Boucher , A Thorell , KL Spalding

kirsty.spalding@ki.se Nat Med 2021; 27(11): 1941–1953 doi: 10.1038/s41591-021-01501-8Brief Summary: This study analysed adipocytes from obese and hyperinsulinemic adults. They demonstrate that obesity is associated with the induction of a cell cycle program in mature adipocytes, leading to so-called endoreplication, as a strategy to remain fu...

ey0020.2-10 | Long-Acting Growth Hormone (LAGH) | ESPEYB20

2.10. Long-acting PEGylated growth hormone in children with idiopathic short stature

X Luo , S Zhao , Y Yang , G Dong , L Chen , P Li , F Luo , C Gong , Z Xu , X Xu , H Gong , H Du , L Hou , Y Zhong , Q Shi , X Chen , X Chen , L Xu , R Cheng , C Su , Y Ma , L Xu , L Zhang , H Lu

Brief summary: This randomized, multicenter, controlled, phase II study compared the effects of high-dose (HD) once-weekly PEGylated-recombinant human growth hormone (PEG-rhGH) to low-dose (LD) and to an untreated control group of children with idiopathic short stature (ISS) over a period of 52 weeks. PEG-rhGH was effective in increasing height gain in a dose dependent manner with both doses being well tolerated during the observation period.PEG-rhGH is ...